Article
Immunology
Hidefumi Kato, Megumi Hayashi, Wataru Ohashi, Takamasa Yamaguchi, Satomi Tanaka, Ayumi Kozono, Siqiang Gao, Akiko Katai, Reiko Niwa, Tomohito Matsuo, Kazuki Ishiyama, Takanori Ando, Mika Ogawa, Takayuki Nakayama
Summary: This study found that risk factors for adverse reactions associated with IVIG therapy include female sex, adult age, high dose IVIG, autoimmune disease, and neuromuscular disease. Multivariate logistic regression identified neuromuscular disease as a significant factor for adverse reactions to IVIG.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Valeria Morales-Ruiz, Victor Hugo Juarez-Vaquera, Marcos Rosetti-Sciutto, Fausto Sanchez-Munoz, Laura Adalid-Peralta
Summary: This study compared the efficacy of intravenous immunoglobulin (IVIg) administration with corticosteroids, plasmapheresis, and placebo in treating autoimmune neurological diseases. The meta-analysis showed that IVIg treatment was beneficial for patient improvement compared to placebo, had similar effects to plasmapheresis, and had no significant difference in efficacy compared to corticosteroid treatment.
AUTOIMMUNITY REVIEWS
(2022)
Article
Dermatology
Victoria P. Werth, Donna A. Culton, Josef S. S. Concha, James S. Graydon, Laurence J. Blumberg, Joyce Okawa, Michal Pyzik, Richard S. Blumberg, Russell P. Hall
Summary: ALXN1830 treatment in pemphigus showed rapid and significant improvement in disease area index scores, accompanied by reductions in certain blood markers, demonstrating notable efficacy and good tolerability.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2021)
Review
Immunology
Maria Maslinska, Joanna Dmowska-Chalaba, Michal Jakubaszek
Summary: The role of IgG4 in IgG4-RD and other autoimmune diseases has attracted attention. IgG4, as a unique subclass of immunoglobulins, is generally considered non-inflammatory and tolerance inducing, but in IgG4-RD, it may play a pathogenic role in fibrogenesis and inflammation.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Dermatology
Nika Kianfar, Shayan Dasdar, Maryam Daneshpazhooh, Zeinab Aryanian, Azadeh Goodarzi
Summary: Autoimmune bullous diseases (AIBDs) are rare blistering dermatoses that affect the mucous membrane and/or skin. This study systematically reviewed the available literature to explore the efficacy, safety, and treatment durability of intravenous immunoglobulin (IVIg) as an alternative treatment for AIBD patients. The study included 60 studies with a total of 747 patients, and the results showed that IVIg alone or in combination with rituximab had favorable clinical responses in AIBD patients, with disease remission rates ranging from 78.6% to 100%. IVIg-related side effects were reported in 37.5% of patients, with headaches, fever/chills, and nausea/vomiting being the most common. Overall, IVIg appeared to be a reasonable treatment option for AIBDs with a low risk of major immune system influence.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Medicine, General & Internal
Cesar Picado, Inaki Ortiz de Landazuri, Alexandru Vlagea, Irina Bobolea, Ebymar Arismendi, Rosanel Amaro, Jacobo Sellares, Joan Bartra, Raimon Sanmarti, Jose Hernandez-Rodriguez, Jose-Manuel Mascaro, Jordi Colmenero, Eva C. Vaquero, Mariona Pascal
Summary: This study highlights the clinical manifestations of Selective IgE deficiency (SIgED), which include various infectious diseases, autoimmune conditions, eczematous dermatitis, and malignancies. Patients with SIgED have an increased risk of developing malignancies, warranting further prospective studies to better characterize this condition and determine its inclusion in the list of antibody deficiencies.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Maciej Marek Spalek, Monika Bowszyc-Dmochowska, Marian Dmochowski
Summary: This study aimed to evaluate the benefits and safety profiles of high-dose IVIG therapy in AIBD patients. The results showed that IVIG treatment can reduce hormone dosage and effectively control the disease. However, the high cost of IVIG limits its application in low-income countries.
MEDICINA-LITHUANIA
(2023)
Article
Immunology
Maria Giovanna Danieli, Eleonora Antonelli, Stefania Auria, Elena Buti, Yehuda Shoenfeld
Summary: IVIg is commonly used as a replacement therapy for immunodeficiencies. It also has an immunomodulatory effect at higher doses, controlling autoimmune and inflammatory diseases. However, cost and accessibility issues, as well as the impact of decreased plasma donations, pose challenges.
AUTOIMMUNITY REVIEWS
(2023)
Review
Medicine, Research & Experimental
Danqi Li, Yuchen Lou, Yamin Zhang, Si Liu, Jun Li, Juan Tao
Summary: Human immunoglobulin G (IgG), especially sialylated IgG, plays a crucial role in the diagnosis and management of autoimmune diseases by exerting significant anti-inflammatory effects. Current research indicates that IgG Fc N-glycosylations are more reliable diagnostic and monitoring biomarkers than total IgG autoantibodies. IgG sialylation-based therapies show promise in attenuating pathogenic autoimmunity in preclinical and clinical studies.
Article
Rheumatology
Arsene Mekinian, Lucie Biard, Dagna Lorenzo, Pavel Novikov, Carlo Salvarani, Olivier Espitia, Savino Sciascia, Martin Michaud, Marc Lambert, Jose Hernandez-Rodriguez, Nicolas Schleinitz, Abid Awisat, Xavier Puechal, Achille Aouba, Helene Munoz Pons, Ilya Smitienko, Jean Baptiste Gaultier, Le Mouel Edwige, Ygal Benhamou, Antoinette Perlat, Patrick Jego, Tiphaine Goulenok, Karim Sacre, Bertrand Lioger, Nolan Hassold, Jonathan Broner, Virginie Dufrost, Thomas Sene, Julie Seguier, Francois Maurier, Sabine Berthier, Alexandre Belot, Faten Frikha, Guillaume Denis, Alexandra Audemard-Verger, Isabelle Kone-Paut, Sebastien Humbert, Pascal Woaye-Hune, Alessandro Tomelleri, Elena Marina Baldissera, Masataka Kuwana, Alberto Logullo, Vahan Mukuchyan, Azeddine Dellal, Francis Gaches, Pierre Zeminsky, Elena Galli, Moya Alvarado, Luigi Boiardi, Muratore Francesco, Mathieu Vautier, Campochiaro Corrado, Sergey Moiseev, Matheus Vieira, Patrice Cacoub, Olivier Fain, David Saadoun
Summary: In this study, the effectiveness and safety of tocilizumab were compared between intravenous and subcutaneous administration in 109 Takayasu arteritis patients. The results showed that both intravenous and subcutaneous tocilizumab achieved complete remission in TAK patients, but the risk of relapse was higher in the subcutaneous group.
Review
Biochemistry & Molecular Biology
Anne Bordron, Marie Morel, Cristina Bagacean, Maryvonne Dueymes, Pierre Pochard, Anne Harduin-Lepers, Christophe Jamin, Jacques-Olivier Pers
Summary: Sialylation plays a crucial role in autoimmunity, with hyposialylation often leading to inflammation and organ damage. A better understanding of this mechanism will help improve treatment strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Jierui Wang, Yu Zhang, Minjin Wang, Yan Ren, Meng Tang, Ling Liu, Dong Zhou
Summary: This study compared the efficacy of intravenous immunoglobulin (IVIG) combined with antiretroviral therapy (ART) versus ART alone in patients with HIV-associated Guillain-Barre syndrome (GBS). The results showed that patients in the IVIG + ART group had significantly lower GBS disability scale grades compared to those in the ART alone group. Moreover, a higher proportion of patients in the IVIG + ART group were able to walk independently after four weeks of treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Salman Aljarallah, Scott D. Newsome
Summary: This case series demonstrates that SCIg could be a viable treatment option for patients with SPS who are intolerant to IVIG. The study shows that SCIg was generally well-tolerated and led to stable SPS symptoms in most patients, highlighting the need for further prospective controlled studies to confirm the durability and efficacy of SCIg treatment.
Article
Immunology
Yusuke Mimura, Yuka Mimura-Kimura, Radka Saldova, Pauline M. Rudd, Roy Jefferis
Summary: Intravenous immunoglobulin (IVIG) modulates immune responses through Fc gamma receptor IIIa blockade and nonfucosylated IgG glycoforms show higher affinity and inhibitory potency in antibody-dependent cellular cytotoxicity (ADCC). This study provides insights into improved therapeutic strategies for autoimmune/inflammatory diseases using glycoengineered IVIG and recombinant Fc.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Leonardo S. Hoff, Fernando H. C. de Souza, Renata Miossi, Samuel K. Shinjo
Summary: This study aimed to evaluate the long-term effects of pulse intravenous methylprednisolone (IVMP) or intravenous immunoglobulin (IVIG) in patients with dermatomyositis (DM) and polymyositis (PM) during the first year of diagnosis. The results showed that patients who received early pulse IVMP or pulse IVMP + IVIG had a higher hazard ratio for complete clinical response, while the combination of pulse IVMP + IVIG was associated with discontinuation of corticosteroids.
Review
Immunology
Xiangye Zhao, Kewei Ma, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Yinghui Xu
Summary: Immunotherapy may lead to pseudoprogression, where tumors initially grow but shrink with continued treatment. This article reports a case of pseudoprogression in a lung cancer patient receiving immunotherapy, and reviews the mechanisms, clinical manifestations, and prognostic indicators of pseudoprogression.
Article
Immunology
Ling-zhijie Kong, Ying Zheng, Kaichun Li
Summary: Treatment options for metastatic colorectal cancer are limited after second-line chemotherapy failure. In this case report, a 59-year-old male patient achieved remarkable response to fruquintinib and toripalimab combination therapy after multiple lines of chemotherapy failed. The patient had partial response within 3 months and complete response of pulmonary masses within 12 months. The combination of fruquintinib and PD-1 inhibitors improves the prognosis of metastatic colorectal cancer, with a progression-free survival of over 17 months.
